Form 8-K - Current report:
SEC Accession No. 0001213900-25-030101
Filing Date
2025-04-09
Accepted
2025-04-09 08:30:37
Documents
15
Period of Report
2025-04-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0237417-8k_180life.htm   iXBRL 8-K 49759
2 CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE DATED APRIL 6, 2025, BETWEEN 180 L ea023741701ex10-1_180life.htm EX-10.1 119379
  Complete submission text file 0001213900-25-030101.txt   415947

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnf-20250406.xsd EX-101.SCH 3786
4 XBRL DEFINITION FILE atnf-20250406_def.xml EX-101.DEF 26628
5 XBRL LABEL FILE atnf-20250406_lab.xml EX-101.LAB 36679
6 XBRL PRESENTATION FILE atnf-20250406_pre.xml EX-101.PRE 25252
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0237417-8k_180life_htm.xml XML 5806
Mailing Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306
Business Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

EIN.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38105 | Film No.: 25823900
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)